advertisement
The potential for neuroprotection in the treatment of glaucoma outside of the lowering of intraocular pressure has been demonstrated in a wide variety of pre-clinical studies. While we are only now beginning to test these strategies in clinical trials, neurologists and neurosurgeons have applied neuroprotective strategies for several years to a variety of neurological diseases, with limited success. By looking at the successes and failures in the evaluation of neuroprotectant in neurological diseases, we may be able to develop improved strategies both in pre-clinical testing and clinical trials in order to evaluate these agents and to maximize the likelihood of implementing a successful neuroprotective agent for the management of glaucoma.
Dr C.A. Girkin, University of Alabama, UAB Department of Ophthalmology, Eye Foundation Hospital, 700 South 18th Street, Birmingham, AL, USA. cgirkin@uabmc.edu
11.8 Neuroprotection (Part of: 11 Medical treatment)